HUP0402341A3 - Compositions containing thiazol-2-ylamines for the treatment of cancer - Google Patents
Compositions containing thiazol-2-ylamines for the treatment of cancerInfo
- Publication number
- HUP0402341A3 HUP0402341A3 HU0402341A HUP0402341A HUP0402341A3 HU P0402341 A3 HUP0402341 A3 HU P0402341A3 HU 0402341 A HU0402341 A HU 0402341A HU P0402341 A HUP0402341 A HU P0402341A HU P0402341 A3 HUP0402341 A3 HU P0402341A3
- Authority
- HU
- Hungary
- Prior art keywords
- ylamines
- cancer
- treatment
- compositions containing
- thiazol
- Prior art date
Links
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31636901P | 2001-08-31 | 2001-08-31 | |
PCT/US2002/026155 WO2003020272A1 (en) | 2001-08-31 | 2002-08-13 | Compositions and methods for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0402341A2 HUP0402341A2 (hu) | 2005-02-28 |
HUP0402341A3 true HUP0402341A3 (en) | 2005-11-28 |
Family
ID=23228767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0402341A HUP0402341A3 (en) | 2001-08-31 | 2002-08-13 | Compositions containing thiazol-2-ylamines for the treatment of cancer |
Country Status (10)
Country | Link |
---|---|
US (1) | US20030114504A1 (hu) |
EP (1) | EP1429764A1 (hu) |
JP (1) | JP2005504065A (hu) |
BG (1) | BG108605A (hu) |
CZ (1) | CZ2004287A3 (hu) |
EE (1) | EE200400074A (hu) |
HU (1) | HUP0402341A3 (hu) |
PL (1) | PL368035A1 (hu) |
SK (1) | SK1102004A3 (hu) |
WO (1) | WO2003020272A1 (hu) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO1999001124A1 (en) * | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
PT1767535E (pt) | 2002-08-23 | 2010-02-24 | Sloan Kettering Inst Cancer | Síntese de epotilonas, respectivos intermediários, análogos e suas utilizações |
DE602004028907D1 (de) * | 2003-02-06 | 2010-10-14 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
US20080113874A1 (en) * | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
US8017321B2 (en) * | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
US20080090233A1 (en) * | 2004-05-27 | 2008-04-17 | The Regents Of The University Of Colorado | Methods for Prediction of Clinical Outcome to Epidermal Growth Factor Receptor Inhibitors by Cancer Patients |
EP1861094A4 (en) * | 2005-03-11 | 2014-06-11 | Univ Colorado | HISTONDEACETYLASE INHIBITORS SENSITIZE CANCER CELLS FOR EPIDERMAL GROWTH FACTOR INHIBITORS |
WO2008036954A1 (en) * | 2006-09-21 | 2008-03-27 | Sunesis Pharmaceuticals, Inc. | Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide |
WO2010012777A1 (en) | 2008-07-29 | 2010-02-04 | Nerviano Medical Sciences S.R.L. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1088049A (en) * | 1975-06-03 | 1980-10-21 | Takashi Masugi | 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof |
US4214852A (en) * | 1978-04-20 | 1980-07-29 | General Electric Company | Variable turbine vane assembly |
US6262096B1 (en) * | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US7312237B2 (en) * | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
-
2002
- 2002-08-13 PL PL02368035A patent/PL368035A1/xx not_active Application Discontinuation
- 2002-08-13 EP EP02759384A patent/EP1429764A1/en not_active Withdrawn
- 2002-08-13 JP JP2003524579A patent/JP2005504065A/ja active Pending
- 2002-08-13 WO PCT/US2002/026155 patent/WO2003020272A1/en not_active Application Discontinuation
- 2002-08-13 SK SK110-2004A patent/SK1102004A3/sk unknown
- 2002-08-13 HU HU0402341A patent/HUP0402341A3/hu unknown
- 2002-08-13 CZ CZ2004287A patent/CZ2004287A3/cs unknown
- 2002-08-13 EE EEP200400074A patent/EE200400074A/xx unknown
- 2002-08-27 US US10/228,544 patent/US20030114504A1/en not_active Abandoned
-
2004
- 2004-02-25 BG BG108605A patent/BG108605A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005504065A (ja) | 2005-02-10 |
CZ2004287A3 (cs) | 2004-10-13 |
PL368035A1 (en) | 2005-03-21 |
US20030114504A1 (en) | 2003-06-19 |
SK1102004A3 (sk) | 2005-05-05 |
EP1429764A1 (en) | 2004-06-23 |
HUP0402341A2 (hu) | 2005-02-28 |
EE200400074A (et) | 2004-06-15 |
BG108605A (bg) | 2005-03-31 |
WO2003020272A1 (en) | 2003-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251270A0 (en) | Cancer treatment | |
PL375532A1 (en) | Benzimidazol-1-yl-thiophene compounds for the treatment of cancer | |
AU6147401A (en) | Compositions and methods for the treatment of cancer | |
HUP0401514A3 (en) | Pharmaceutical compositions for the treatment of asthma | |
HUP0400314A3 (en) | Pharmaceutical combinations for the treatment of cancer | |
GB0128722D0 (en) | Seed treatment compositions | |
EG23562A (en) | Seed treatment compositions | |
GB0128390D0 (en) | Seed treatment compositions | |
HUP0500424A2 (en) | Combination therapy for the treatment of cancer | |
IL164896A (en) | Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors | |
HUP0400609A3 (en) | Wet-skin treatment compositions | |
EP1442062A4 (en) | METHOD FOR TREATING CARCINOMA | |
EP1476067A4 (en) | COMPOSITIONS AND METHODS FOR CANCER | |
EP1509539A4 (en) | COMPOSITIONS AND METHODS RELATING TO CANCER | |
HUP0402341A3 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
IL165839A0 (en) | Compounds useful for the treatment of cancer compositions thereof and methods therewith | |
IL145397A0 (en) | Compositions and methods for treatment of cancer | |
EP1469769A4 (en) | NEW COMPOSITIONS AND METHODS AGAINST CANCER | |
AU2002365093A8 (en) | Therapeutic compositions | |
HUP0500199A2 (en) | Pharmaceutical composition comprising arsenite for the treatment of malignancy | |
EP1469870A4 (en) | NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
AU2003270202A8 (en) | Pharmaceutical compositions useful for the treatment of cancers | |
AU2002304883A1 (en) | Device for the treatment of tumours | |
GB0109428D0 (en) | Therapeutic compositions | |
AU2003240174A8 (en) | Compositions for the treatment of edematous-firbrosclerotic panniculopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |